{
  "success": true,
  "sourceFile": "input/Alexion_NCT04573309_Wilsons_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gemini-2.5-pro",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "populationType": "Disposition",
        "instanceType": "AnalysisPopulation",
        "description": "The Screened Set will include all participants who signed an informed consent form (ICF).",
        "criteria": "Signed an informed consent form (ICF)"
      },
      {
        "id": "pop_2",
        "name": "Enrolled Set",
        "populationType": "Disposition",
        "instanceType": "AnalysisPopulation",
        "description": "The Enrolled Set will include all participants who were enrolled in the study.",
        "criteria": "Enrolled in the study"
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FA",
        "description": "The Full Analysis (FA) Set will include all participants who were enrolled and received at least 1 dose of study drug. The FA Set will be the primary population for all efficacy analyses.",
        "criteria": "Enrolled and received at least 1 dose of study drug"
      },
      {
        "id": "pop_4",
        "name": "Per Protocol Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP",
        "description": "The Per Protocol (PP) Set will include all participants in the FA Set who have no major protocol deviations that would impact the primary efficacy endpoint. The PP Set will be used for sensitivity analyses of the primary efficacy endpoint.",
        "criteria": "In the FA Set and have no major protocol deviations that would impact the primary efficacy endpoint"
      },
      {
        "id": "pop_5",
        "name": "Safety Set",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "description": "The Safety Set will include all participants who received at least 1 dose of study drug. The Safety Set will be the primary population for all safety analyses.",
        "criteria": "Received at least 1 dose of study drug"
      },
      {
        "id": "pop_6",
        "name": "Pharmacokinetic Analysis Set",
        "populationType": "Pharmacokinetic",
        "instanceType": "AnalysisPopulation",
        "label": "PK",
        "description": "The Pharmacokinetic (PK) Analysis Set will include all participants in the Safety Set who have sufficient plasma concentration data to allow for the derivation of at least 1 PK parameter. The PK Analysis Set will be used for all PK analyses.",
        "criteria": "In the Safety Set and have sufficient plasma concentration data to allow for the derivation of at least 1 PK parameter"
      },
      {
        "id": "pop_7",
        "name": "Pharmacodynamic Analysis Set",
        "populationType": "Pharmacodynamic",
        "instanceType": "AnalysisPopulation",
        "label": "PD",
        "description": "The Pharmacodynamic (PD) Analysis Set will include all participants in the Safety Set who have sufficient PD data to allow for the derivation of at least 1 PD parameter. The PD Analysis Set will be used for all PD analyses.",
        "criteria": "In the Safety Set and have sufficient PD data to allow for the derivation of at least 1 PD parameter"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age in years, calculated as: (date of informed consent – date of birth + 1)/365.25, truncated to the integer."
      },
      {
        "id": "char_2",
        "name": "Sex",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Sex of the participant."
      },
      {
        "id": "char_3",
        "name": "Race",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Race of the participant."
      },
      {
        "id": "char_4",
        "name": "Ethnicity",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Ethnicity of the participant."
      },
      {
        "id": "char_5",
        "name": "Weight",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline weight of the participant."
      },
      {
        "id": "char_6",
        "name": "Height",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline height of the participant."
      },
      {
        "id": "char_7",
        "name": "Body Mass Index (BMI)",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline Body Mass Index (BMI), calculated as weight (kg) / [height (m)]^2."
      },
      {
        "id": "char_8",
        "name": "Cohort",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Baseline disease characteristic defining participant cohort (treatment experienced or treatment naïve)."
      },
      {
        "id": "char_9",
        "name": "Medical/Surgical History",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Medical and surgical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA)."
      },
      {
        "id": "char_10",
        "name": "Prior Medications",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Prior medications are those that stopped before the first dose of study drug."
      },
      {
        "id": "char_11",
        "name": "Prior medications for Wilson Disease",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Prior medications used to treat Wilson Disease (WD) will be summarized separately."
      },
      {
        "id": "char_12",
        "name": "Baseline Value",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Unless otherwise specified, the baseline value for a parameter is defined as the last non-missing measurement collected prior to the first dose of study drug."
      }
    ],
    "summary": {
      "populationCount": 7,
      "characteristicCount": 12
    }
  }
}